 Connection
Andrey Soares to Carcinoma, Transitional Cell
This is a "connection" page, showing publications Andrey Soares has written about Carcinoma, Transitional Cell.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.462 |
|
|
|
-
Mollica V, Massari F, Fujita K, Giannatempo P, Grande E, Büttner T, Bourlon MT, Taha T, Fukuokaya W, Myint ZW, Pichler R, Binz K, Molina-Cerrillo J, Kopecky J, de Liaño AG, Kucharz J, Fiala O, Matrana MR, Kopp RM, Di Civita MA, Zgura A, Ansari J, Kihnel R, De Felice F, Angel M, Monteiro FSM, Soares A, Urun Y, Buti S, Santini D, Santoni M. Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). Cancer Immunol Immunother. 2026 Mar 24; 75(4).
Score: 0.231
-
Cerbone L, Roviello G, Calabrò F, Taha T, Grande E, Binz K, Kanesvaran R, Pirstuk A, Fiala O, Molina-Cerrillo J, Alonso-Gordoa T, Rizzo A, Pichler R, Myint ZW, Poprach A, Facchini G, Bohuslav M, Studentova H, Morelli F, Buchler T, Mennitto A, Tural D, Formisano L, Orejana I, Catalano M, Buti S, Monteiro FSM, Soares A, Gupta S, Massari F, Santoni M. Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario? Front Immunol. 2026; 17:1667155.
Score: 0.230
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|